Payment overview · 2025
General Payments
$480.92
15 reported records · 8 companies
Healthcare provider profile · identity verified
Narendra Sankar, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DEWEY, AZ · NPI 1437313723
Verified facts
What the public records show
CMS Open Payments records show Narendra Sankar, M.D. received $480.92 in general payments during 2025 across 15 reported records.
Abbott Laboratories accounted for 46.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $223.68 | 46.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $122.06 | 25.4% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.21 | 8.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $23.23 | 4.8% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.61 | 4.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.89 | 4.3% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.48 | 3.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.76 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $480.92 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $121.15 | 1 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $102.53 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $57.94 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $46.19 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $38.21 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $23.23 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $23.23 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $22.61 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 792 | 239 |
| Levothyroxine Sodium | Levothyroxine Sodium | 685 | 190 |
| Atorvastatin Calcium | Atorvastatin Calcium | 599 | 181 |
| Amlodipine Besylate | Amlodipine Besylate | 439 | 130 |
| Lisinopril | Lisinopril | 435 | 124 |
| Losartan Potassium | Losartan Potassium | 402 | 117 |
| Omeprazole | Omeprazole | 300 | 91 |
| Tamsulosin Hcl | Tamsulosin Hcl | 278 | 88 |
| Simvastatin | Simvastatin | 268 | 78 |
| Metformin Hcl | Metformin Hcl | 261 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 235 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 227 | 65 |
| Gabapentin | Gabapentin | 210 | 71 |
| Prednisone | Prednisone | 184 | 120 |
| Ezetimibe | Ezetimibe | 183 | 58 |
| Famotidine | Famotidine | 183 | 59 |
| Tizanidine Hcl | Tizanidine Hcl | 159 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 125 | 40 |
| Furosemide | Furosemide | 120 | 41 |
| Finasteride | Finasteride | 119 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 119 | 36 |
| Trulicity | Dulaglutide | 115 | 27 |
| Azithromycin | Azithromycin | 112 | 96 |
| Cephalexin | Cephalexin | 106 | 73 |
| Potassium Chloride | Potassium Chloride | 106 | 35 |
| Atenolol | Atenolol | 102 | 28 |
| Trazodone Hcl | Trazodone Hcl | 102 | 29 |
| Allopurinol | Allopurinol | 101 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 95 | 68 |
| Carvedilol | Carvedilol | 89 | 27 |
| Mounjaro | Tirzepatide | 89 | 13 |
| Meloxicam | Meloxicam | 87 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 34 |
| Montelukast Sodium | Montelukast Sodium | 84 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 80 | 61 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 71 | 61 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 69 | 40 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 67 | 14 |
| Eliquis | Apixaban | 66 | 19 |
| Sertraline Hcl | Sertraline Hcl | 62 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 15 |
| Lovastatin | Lovastatin | 60 | 21 |
| Alendronate Sodium | Alendronate Sodium | 57 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 16 |
| Spironolactone | Spironolactone | 52 | 17 |
| Nystatin | Nystatin | 51 | 30 |
| Cefdinir | Cefdinir | 50 | 35 |
| Valsartan | Valsartan | 50 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 14 |
| Fluconazole | Fluconazole | 45 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 13 |
| Jardiance | Empagliflozin | 44 | 12 |
| Metformin Hcl Er | Metformin Hcl | 44 | 15 |
| Benazepril Hcl | Benazepril Hcl | 42 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 14 |
| Metronidazole | Metronidazole | 42 | 32 |
| Paxlovid | Nirmatrelvir/Ritonavir | 42 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | 12 |
| Ondansetron Odt | Ondansetron | 38 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 14 |
| Synthroid | Levothyroxine Sodium | 35 | 11 |
| Ibuprofen | Ibuprofen | 33 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | 11 |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Euthyrox | Levothyroxine Sodium | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 20 |
| Glimepiride | Glimepiride | 27 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 21 |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 12 |
| Valacyclovir | Valacyclovir Hcl | 22 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | 11 |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $480.92 · 15 records | Abbott Laboratories | AIRSUPRA, BREZTRI, EVENITY, FARXIGA, GALLANT, GEMTESA, JOT DX, NUZYRA, PROLIA, QULIPTA, TRELEGY ELLIPTA, Tlando, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error